Clinical trials: Transfusions
Hip Fractures, Intertrochanteric Fractures
Does Early Administration of Tranexamic Acid Reduce Blood Loss and Perioperative Transfusion Requirement
Intertrochanteric hip fractures typically result in blood loss from the fracture and require surgery that can cause further blood loss.
- Trial name
- NCT03182751
- Testing
- Tranexamic Acid (TXA)
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- Mayo Clinic
Transfusion-dependent Anemia
Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload
This was a randomized, open-label, multicenter, two arm, phase II study to evaluate treatment compliance and change in serum ferritin of a deferasirox granule formulation and a deferasirox dispersible tablet (DT) formulation in…
- Trial name
- NCT02435212
- Testing
- Deferasirox granule formulation, Deferasirox DT formulation
- Where
- 43 sites in United States, Belgium and 15 more
- Volunteers
- 224 people
- Sponsor
- Novartis Pharmaceuticals
Malaria
Clinical and Biological Efficacy of Mirasol-treated Fresh Whole Blood for the Prevention of Transfusion-transmitted Malaria
The trial will evaluate the efficacy of the Mirasol Pathogen Reduction Technology for Whole Blood to prevent Malaria transmission by transfusion of whole blood.
- Trial name
- AIMS (NCT02118428)
- Testing
- Mirasol-treated Whole Blood, Untreated Whole Blood
- Where
- Ghana
- Volunteers
- 227 people
- Sponsor
- Terumo BCTbio
Hematological Malignancies, Thrombocytopenia
PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid)
STUDY BACKGROUND AND PURPOSE: Patients with hematological malignancies (blood-related cancers) often develop thrombocytopenia (low platelet count), which can be made worse by cancer treatment.
- Trial name
- PROBLEMA (NCT02074436)
- Testing
- EACA, Platelet transfusion
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Emory University
Platelet Transfusion Refractoriness (PTR), Thrombocytopenia
The SOLID Platelet Study
Background: Platelets are cell fragments in the blood that help it clot. Some people get very low platelet counts during a disease or treatment. Low platelet counts can cause severe bleeding.
- Trial name
- NCT03712618
- Testing
- Platelet Transfusion - LONG Platelet Transfusion, Platelet Transfusion - SHORT Platelet Transfusion
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Osteoarthritis, Intraoperative Bleeding
Use of a Novel Fibrin Sealant in Total Knee Arthroplasty
Applying a fibrin spray, after knee device implantation, will help in reducing patient blood loss and decrease the drop in both hemoglobin and hematocrit levels.
- Trial name
- NCT01656759
- Testing
- Evicel Fibrin Spray
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Rush University Medical Center
Cold Agglutinin Disease
A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion
The purpose of Part A was to determine whether sutimlimab administration resulted in a greater than or equal to (>=)1.5 grams per deciliter (g/dL) increase in hemoglobin (Hgb) level and avoidance of transfusion in participants…
- Trial name
- Cadenza (NCT03347422)
- Testing
- sutimlimab (BIVV009)
- Where
- 53 sites in United States, Australia and 12 more
- Volunteers
- 42 people
- Sponsor
- Bioverativ, a Sanofi company
Blood Component Transfusion
Immunomodulation Following Transfusion
This study is designed to provide information on patients' immune response after exposure to transfused blood. Blood transfusions may have opposite immune effects on patients. One is sensitization. The other is immunosuppression.
- Trial name
- NCT00810810
- Testing
- Standard blood components, Leukoreduced blood components, Leukoreduced and irradiated
- Where
- 2 sites in United States
- Volunteers
- 287 people
- Sponsor
- University of Washington
Anemia, Myelodysplastic Syndrome
Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome
This phase II trial studies how well deferasirox works in treating patients with very low, low, or intermediate-risk anemia or myelodysplastic syndrome that depends on red blood cell transfusions.
- Trial name
- NCT02943668
- Testing
- Deferasirox, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Fred Hutchinson Cancer Center
Tranexamic Acid, Cancer
TXA Study in Major Oncologic Surgery
Major surgery can result in blood loss that can require a blood transfusion during and/or after surgery. Tranexamic acid is a medication that was first introduced in the 1960s as a treatment for heavy menstrual bleeding.
- Conditions
- Tranexamic Acid, Cancer, Major Surgery
- Trial name
- TXA (NCT01980355)
- Testing
- Tranexamic Acid
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Corewell Health West
Sickle Cell Disease
Biotin-RBC Transfusion in SCD
This is a single-arm, mechanistic clinical trial to measure predictors of senescence and the in vivo survival of transfused red blood cells (RBCs) in individuals with sickle cell disease (SCD) receiving chronic transfusion…
- Trial name
- NCT04426591
- Testing
- Biotin Labeled Red Blood Cells, Pathogen-reduced Biotin Labeled Red Blood Cells
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Marianne Yee
Traumatic Brain Injury, Subarachnoid Hemorrhage
Near Infrared Spectroscopy (NIRS) as Transfusion Indicator in Neurocritical Patients
Neurocritical ill patients are frequently transfused. Red blood cell transfusion (RBCT) in these patients has been associated with deleterious effects, including higher rates of nosocomial infections, multi-organ failure, and…
- Conditions
- Traumatic Brain Injury, Subarachnoid Hemorrhage, Intracerebral Hemorrhage
- Trial name
- NCT00566709
- Testing
- Red blood cells transfusion
- Where
- Spain
- Volunteers
- 102 people
- Sponsor
- Hospitales Universitarios Virgen del Rocío
Healthy
Feasibility Study of Mirasol-Treated Whole Blood Red Cell Recovery and Survival
Feasibility trial to evaluate recovery and survival of red blood cells (RBCs) from Mirasol-treated whole blood
- Trial name
- IMPROVE (NCT00742001)
- Testing
- Mirasol System for Whole Blood.
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Terumo BCTbio
Primary Myelofibrosis, MPN-associated Myelofibrosis
Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence
The objective of this study is to determine whether pomalidomide is safe and effective in reversing red blood cell (RBC)-transfusion-dependence in persons with myeloproliferative neoplasm (MPN)-associated myelofibrosis (global…
- Trial name
- RESUME (NCT01178281)
- Testing
- Pomalidomide 0.5 mg, Pomalidomide
- Where
- 87 sites in United States, Australia and 14 more
- Volunteers
- 267 people
- Sponsor
- Celgene
Cardiac Complication During Procedure
Prospective Double Blinded Randomized Control Study of the Use of Fibrinogen in High-Risk Cardiac Surgery
The aim of the study is to show that first line treatment with concentrated fibrinogen has superiority over the conventional therapy with fresh frozen plasma (FFP), platelets, and cryoprecipitate in perioperative management of…
- Trial name
- NCT01623531
- Testing
- Fibrinogen
- Where
- Canada
- Volunteers
- 62 people
- Sponsor
- Nova Scotia Health Authority
Sickle Cell Anemia
Transcranial Doppler (TCD) With Transfusions Changing to Hydroxyurea
The primary goal of the Phase III TWiTCH trial is to compare 24 months of alternative therapy (hydroxyurea) to standard therapy (transfusions) for pediatric subjects with sickle cell anemia and abnormally high (≥200 cm/sec)…
- Trial name
- TWiTCH (NCT01425307)
- Testing
- Hydroxyurea
- Volunteers
- 159 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Diffuse Large B-cell Lymphoma
Oral Panobinostat Adult Patients DLBCL Relapsed/Refractory Stem Cell Transfusion (ASCT) or Not Eligible for ASCT
Treatment of adult patients with Diffuse Large B-cell Lymphoma (DLBCL), relapsed or refractory to previous CHOP-R (or CHOP-R like regimen) front line therapy, relapsed or refractory to second or subsequent salvage therapies which…
- Trial name
- FIL_PanAL10 (NCT01523834)
- Testing
- Panobinostat
- Where
- 10 sites in Italy
- Volunteers
- 35 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Anemia, Leukemia
Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia
This is a single-center, single arm, open-label study of oral lenalidomide monotherapy administered to red blood cell (RBC) transfusion dependent adult subjects with Diamond-Blackfan Anemia (DBA).
- Conditions
- Anemia, Leukemia, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
- Trial name
- NCT01034592
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Jason Robert Gotlib
Anemia
ORthopaedic Trauma Anemia With Conservative Versus Liberal Transfusion
The purpose of this study is to determine if there is a difference in outcomes between liberal transfusion (transfusing when hemoglobin drops below a set higher value number) and conservative transfusion (transfusing when…
- Trial name
- ORACL (NCT02972593)
- Testing
- Blood and blood products for transfusion
- Volunteers
- 161 people
- Sponsor
- Indiana University
Beta-thalassemia Major, Hemosiderosis
Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)
To allow patients treated with deferasirox in the core study to continue iron chelation therapy for 2 years or until the drug became locally commercially available.
- Conditions
- Beta-thalassemia Major, Hemosiderosis, Iron Overload, Rare Anemia
- Trial name
- ESCALATOR (NCT00171301)
- Testing
- Deferasirox
- Where
- 5 sites in Egypt, Lebanon and 3 more
- Volunteers
- 233 people
- Sponsor
- Novartis Pharmaceuticals